Abstract P215: Presence of Comorbid Psychiatric Illness is Associated with Aortic Vascular Inflammation and Coronary Heart Disease Beyond Traditional Cardiovascular Risk Factors in Psoriasis
Introduction: Psoriasis is a chronic inflammatory disorder associated with vascular inflammation (VI), measured by 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT), and increased risk of MI. Coronary plaque composition by coronary computed tomography angiography (CCTA) predicts both CV risk and outcomes. Patients with psoriasis are more likely to suffer from comorbid depression and anxiety. Whether these comorbidities may accelerate the development of CVD in psoriasis is not well characterized.
Hypothesis: We hypothesized that aortic VI and coronary plaque burden would be increased in patients with psoriasis who have depression and/or anxiety when compared to those with psoriasis who do not.
Methods: Psoriasis patients were derived from an ongoing psoriasis study cohort. Patients who reported a history of depression and/or anxiety (n=40) on survey and age- and gender- matched patients who reported no history of psychiatric illness (n=40) were selected. Target-to-background ratio from FDG PET/CT was used to assess aortic VI and CCTA scans were analyzed for coronary plaque composition. Multivariate linear regression was performed to understand the effect of psychiatric diagnoses on VI and plaque burden after adjustment for CV risk factors (standardized β reported).
Results: In unadjusted analyses, both aortic VI and coronary plaque burden were higher in psoriasis patients with comorbid depression or anxiety compared to those without (Table 1). After adjustment for Framingham Risk Score, body mass index, and statin use, VI (β=0.24, p=0.02), total plaque burden (β=0.13, p=0.04), and non-calcified burden (β=0.13, p=0.04) were associated with comorbid depression or anxiety.
Conclusions: Patients with psoriasis who have comorbid depression or anxiety have increased aortic VI and coronary plaque burden, suggesting that identification of psychiatric diagnoses in psoriasis may be warranted for future CV risk reduction in this high risk population.
Author Disclosures: T.M. Aberra: None. A.A. Joshi: None. J.B. Lerman: None. J.A. Rodante: None. J.I. Silverman: None. T.Z. Aridi: None. M.Y. Chen: None. N.N. Mehta: None.
- © 2016 by American Heart Association, Inc.